Michael S Nakazawa

4PUBLICATIONS
33CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Solid tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (4)

|Jun 26, 2026
Personalized targeting of BCL2 family proteins overcomes acquired resistance to BRAF-MEK inhibitors in preclinical melanoma.

|May 14, 2025
TFCP2 Fusion-Positive Rhabdomyosarcomas: A Report of 10 Cases and a Review of the Literature.

Madison P Ginn, Ryan A Denu, Davis R Ingram

|Aug 06, 2024
Clinical characteristics and outcomes of adult alveolar rhabdomyosarcoma patients on first-line systemic therapies: A single-institution cohort.

Michael S Nakazawa, J Andrew Livingston, Maria A Zarzour

|Apr 01, 2024
Loss of the DNA Repair Gene RNase H2 Identifies a Unique Subset of DDR-Deficient Leiomyosarcomas.

Michael S Nakazawa, Ian M Silverman, Victoria Rimkunas

Pageof 1

Frequent Collaborators

2 joint publications

Anthony P Conley

1 joint publications

Ian M Silverman

1 joint publications

Victoria Rimkunas

1 joint publications

Artur Veloso